Sandoz Patent Expiries May Cut Drug Prices

That is not just a margin story for drugmakers. It is a healthcare affordability story with direct economic consequences. Steenbergen said many medicines are currently not prescribed because they are too expensive, a reminder that patent-driven pricing can restrict access even where clinical demand exists. Lower prices could expand treatment use, reduce payer costs and shift more spending from branded drugs to generics and biosimilars.

The opportunity is especially relevant in biologics, where patent cliffs tend to be slower but more lucrative when they arrive. Sandoz has built much of its case around making versions of expensive biologic drugs as the original products lose protection, and it is fighting a series of legal battles with big pharmaceutical companies it accuses of artificially extending patents. That is a familiar pattern in the industry: branded drugmakers defend exclusivity as long as they can, while challengers wait for the opening.

The market is already pricing in the tension between those two worlds. Novartis, which spun off Sandoz, has long been a heavyweight in innovative medicines, while Pfizer and other large U.S. drugmakers continue to navigate pressure from drug-cost policies and looming competition. The long-term takeaway for investors is simple: patent expiry is often a threat to one company and an opportunity for another.

Sandoz is effectively telling investors to look beyond quarterly noise and toward a multi-year cycle in which affordability, access and volume growth replace monopoly pricing as the central engine of the industry. For long-term investors, that makes the generics and biosimilars theme worth watching closely.